Your comment implies a reduction in the profitability of A for both S & M.
I think that is worthy of a new discussion of what that implies and means.
The more i think about the situation, the more i think the old "reasons" for slow adoption of A are real, but not the real brick wall we are hitting and will continue to hit. That huge wall is insurance. No matter how good A is, if the discounts for early users disappears after an intro, then the cost will stop any growth now, and sour people that now tried but had to drop out because of costs.
I think the fantastic reports from users are good, but i also think that the more i read the more i am concerned that even these very sophisticated and aware type !'s that are going through the efforts to experiment with trial and error and documented efforts are not indicative of what the giant market of type 2's will be willing to do.
Net result of my thinking this through is that neither S or M are currently prepared to hand hold the type 2's through the increasingly complex process of becoming a knowledgeable and successful user of this wonderful drug.
That means they are either oblivious to what is going to be required, or they have been prescient in their awareness that we need a documented experiential record of actual users in order to write the "manual" of how to actually use this wonderful invention.
There are three goals for A. An operating manual (detailed, including "tweaking hints"), higher level insurance coverage, and going back to the first point, education of doctors on all levels on how to manage A.
As great as A is, it is not "take a puff before your meal".